

## **OFFICIAL PRESS PROGRAMME**

(AS OF WENESDAY 13<sup>th</sup> OCTOBER 2021)

**CONFERENCE EMBARGO POLICY:** 

EMBARGO LIFTS ON ALL ORAL ABSTRACTS AT THE BEGINNING OF THE PRESS CONFERENCE THEY ARE PRESENTED IN

All Press conferences will be replayed here:

https://www.youtube.com/playlist?list=PLn2oAgU-emcXJWNhCVeTUmx3v0QlEn8P3

## PLEASE NOTE: PRESS PROGRAMME SUBJECT TO CHANGES

TIME (CEST)	THEME / TOPIC	TIME OF PRESENTATIONS	SPEAKERS
TUESDAY OCTOBER 19 09:30 – 10:15 CEST	52 <sup>nd</sup> Union World Conference on Lung Health Official Press Conference <b>Official Opening Press Conference:</b> <i>COVID-19 and TB: Aerosol transmission, zoonotic</i> <i>transmission and testing</i>		<ul> <li>Chair: Guy Marks, President, the Union.</li> <li>Speakers:</li> <li>Tereza Kasaeva, Director, World Health Organization (WHO) Global TB programme.</li> <li>Uvistra Naidoo, Pediatric doctor, TB and COVID-19 survivor, Cape Town, South Africa.</li> <li>Claire Forlani, Film &amp; TV actress, TB Ambassador, The Union, UK.</li> </ul>
	Cough-independent aerosolization of <em>Mycobacterium tuberculosis</em> suggests a significant role for tidal breathing in asymptomatic tuberculosis transmission (TBS-08-04)	Thursday October 21 16:40 – 17:25	<b>Ryan Dinkele</b> , Institute of infectious disease and molecular medicine, University of Cape Town, South Africa.
	Tuberculosis at a human-bear interface in Cambodia (OA10-663-19)	Tuesday October 19 16:30 – 17:50	<b>Kirsty Officer</b> , School of Veterinary and life Sciences, Murdoch University, Perth, Australia.
	Diagnostic accuracy of the Cepheid 3 gene host-response fingerstick blood test in a prospective, multi-site study ( LB-1786-22)	Friday October 22 15:00 – 16:20	Jayne Sutherland, Head of the TB research group at the MRC Unit in The Gambia, UK.

TIME (CEST)	THEME / TOPIC	TIME OF PRESENTATION S	SPEAKERS
WEDNESDAY OCTOBER 20 10:30 – 11:15 CEST	52 <sup>nd</sup> Union World Conference on Lung Health Official Press Conference		<b>Chair: Ingrid Shoeman (Chair)</b> , The Union's Community Advisory Panel (UCAP), Johannesburg, South Africa.
	Short all-oral treatment for Rifampicin Resistant Tuberculosis. Results from TB-PRACTECAL, a Phase II-III multicentre randomised controlled trial of a 24-week BPaLM regimen	Friday October 22 15:00 – 16:20	Speakers: Bern-Thomas Nyang'wa, Medical Director of Médecins Sans Frontières (MSF-OCA), UK.
	Development of Artificial Intelligence for Screening Active Tuberculosis on CT Images (OA28-792-22)	Friday October 22 11:00 – 12:20	<b>Fleming Lure,</b> Dr. Investigator at MS Technologies Corp, Shenzhen Zhying Medical Imaging, Guangdong, China.
	Feasibility and yield of systematic tuberculosis molecular testing in children with severe pneumonia in countries with high tuberculosis incidence (OA24-760-21)	Thursday October 21 16:30 – 17:50	<b>Aurélia Vessière,</b> researcher in infectious diseases epidemiology, University of Bordeaux, France.
	Genomic signatures of pre-resistance in Mycobacterium tuberculosis (TBS-LB-04)	Friday October 22 12:00 – 13:30	<b>Arturo Torres Ortiz,</b> PHD Student, Imperial College London, UK.
	Efficacy and safety of 4-month rifapentine-moxifloxacin regimen for tuberculosis in adolescent participants (OA23-753-21)	Thursday October 21 15:00 – 16:20	<b>Kimberly Hedges,</b> Health Scientist, Centers for Disease Control and Prevention, Division of TB Elimination, Atlanta, Georgia, U.S.
	Face mask sampling of pulmonary tuberculosis patients predicts acquired <i>Mycobacteriumtuberculosis</i> infection in household contacts (TBS-08-01)	Thursday October 21 16:40 – 17:25	<b>Caroline Williams</b> , University of Leicester, UK.